Willkommen, schön sind Sie da!
Logo Ex Libris

Current Advances in Osteosarcoma

  • E-Book (pdf)
  • 359 Seiten
(0) Erste Bewertung abgeben
Bewertungen
(0)
(0)
(0)
(0)
(0)
Alle Bewertungen ansehen
Current Advances in Osteosarcoma edited by Dr. Eugenie S. Kleinerman summarizes molecular and genetic characteristics, new therape... Weiterlesen
E-Books ganz einfach mit der kostenlosen Ex Libris-Reader-App lesen. Hier erhalten Sie Ihren Download-Link.
CHF 131.90
Download steht sofort bereit
Informationen zu E-Books
E-Books eignen sich auch für mobile Geräte (sehen Sie dazu die Anleitungen).
E-Books von Ex Libris sind mit Adobe DRM kopiergeschützt: Erfahren Sie mehr.
Weitere Informationen finden Sie hier.

Beschreibung

Current Advances in Osteosarcoma edited by Dr. Eugenie S. Kleinerman summarizes molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and it is also the most common histological form of bone cancer. It accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents. The lungs are the most common site of metastases and once osteosarcoma spreads to the lungs, it is very difficult to treat. To improve the outcome of this disease, the biology of osteosarcoma needs to be better understood. There are numerous investigators around the world who have made seminal discoveries about the important molecular pathways and genetic alterations that contribute to the development and metastases of osteosarcoma. Other investigators have proposed novel therapeutic strategies including some based on the molecular and genetic phenotype of the disease. Current Advances in Osteosarcoma summarizes all of these new discoveries in one singular text, which will help move the field forward.

Eugenie S. Kleinerman, M.D. is Professor and Head of the Division of Pediatrics, the first women Division Head at MD Anderson Cancer Center. She is board certified in pediatrics, holds the Mosbacher Pediatrics Chair and is also a Professor of Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an FDA advisory panel. She has authored over 177 articles and 21 book chapters and has received over 2900 citations. In 2006, her achievements were recognized by her alma mater, Duke University Medical Center, where she received the Distinguished Medical Alumnus Award. She is the 2009 recipient of the Faculty Achievement Award in Clinical Research.

Autorentext
Eugenie S. Kleinerman, M.D. is Professor and Head of the Division of Pediatrics, the first women Division Head at MD Anderson Cancer Center. She is board certified in pediatrics, holds the Mosbacher Pediatrics Chair and is also a Professor of Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an FDA advisory panel. She has authored over 177 articles and 21 book chapters and has received over 2900 citations. In 2006, her achievements were recognized by her alma mater, Duke University Medical Center, where she received the Distinguished Medical Alumnus Award. She is the 2009 recipient of the Faculty Achievement Award in Clinical Research.

Klappentext

Current Advances in Osteosarcoma summarizes  molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in this field over the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and is the most common histological form of bone cancer. Osteosarcoma accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents. The lungs are the most common site of metastases and once osteosarcoma spreads to the lungs, it is very difficult to treat.

 

In order to improve the outcome of this disease, the biology of osteosarcoma needs to be better understood. There are numerous investigators around the world who have made seminal discoveries about the important molecular pathways and genetic alterations that contribute to the development and metastases of osteosarcoma. Other investigators have proposed novel therapeutic strategies including some based on the molecular and genetic phenotype of the disease. This volume will ?provide a comprehensive review of these new discoveries in one singular text, which will help move the field forward.



Inhalt

Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma
Norman Jaffe

Wnt Signaling in Osteosarcoma
Carol H Lin, Tao Ji, Cheng-Fong Chen, Bang H Hoang

Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects
Ashley N. Rettew, Patrick J Getty, and Edward M. Greenberg

Understanding the Role of Notch in Osteosarcoma
Madonna M McManus, Kurt R Weiss, and Dennis PM Hughes

Developmental Pathways Highjacked by Osteosarcoma
Yi Zhang, Jared R Mortus, and Dennis PM Hughes

MicroRNAs in Osteosarcomagenesis
Lisa A Kafchinski and Kevin B Jones

RECQ DNA Helicases and Osteosarcoma
Linchao Lu, Weidong Jin, Hao Liu, and Lisa L Wang

Autophagy in Osteosarcoma
Janice Santiago O'Farrill and Nancy Gordon

HER-2 Involvement in Osteosarcoma
Jonathan Gill, David Geller, and Richard Gorlick

Role of Ezrin in Osteosarcoma Metastasis
Ling Ren and Chand Khanna

Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases
Gangxiong Huang, Kazumasa Nishimoto, Yuanzheng Yang, and Eugenie S Kleinerman?

Zebrafish as a Model for Human Osteosarcoma
AB Mohseny and Pancras CW Hogendoorn

Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?
Carlos O Rodriguez

Oncolytic Viruses for Potential Osteosarcoma Therapy
Pooja Hingorani, Valerie Sampson, Christina Lettieri, E. Anders Kolb

IL-11R?: A Novel Target for the Treatment of Osteosarcoma
Valerae Lewis

Bone-seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223
Peter M Anderson, Vivek Subbiah, and Eric Rohren

Muramyl Tripeptide-phophatidyl Ethanolamine Encapsulated in Lipomes (L-MTP-PE) in the Treatment of Osteosarcoma
Paul A Meyers

Genetically Modified T-cell Therapy for Osteosarcoma
Christopher DeRenzo and Stephen Gottschalk

Natural Killer Cells for Osteosarcoma
Nidale Tarek, and Dean A Lee.

Produktinformationen

Titel: Current Advances in Osteosarcoma
Editor:
EAN: 9783319048437
ISBN: 978-3-319-04843-7
Digitaler Kopierschutz: Wasserzeichen
Format: E-Book (pdf)
Herausgeber: Springer
Genre: Medizin
Anzahl Seiten: 359
Veröffentlichung: 12.06.2014
Jahr: 2014
Untertitel: Englisch
Dateigrösse: 7.9 MB